Targeted Oncology

, Volume 12, Issue 6, pp 839–840 | Cite as

Comment on: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”

  • Arnaud Uguen
Letter to the Editor


Compliance with Ethical Standards



Conflict of Interest

The author declares no conflict of interest.


  1. 1.
    Auliac JB, Monnet I, Dubos-Arvis C, et al. Non-small cell lung cancer (NSCLC) harboring ALK translocations: clinical characteristics and management in a real-life setting: a French retrospective analysis (GFPC 02-14 study). Target Oncol. 2017;
  2. 2.
    Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 2014;9(3):295–306.CrossRefPubMedGoogle Scholar
  3. 3.
    Ilie MI, Bence C, Hofman V, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol. 2015;26(1):238–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Lantuejoul S, Rouquette I, Blons H, et al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46:207–18.CrossRefPubMedGoogle Scholar
  5. 5.
    Uguen A, Andrieu-Key S, Vergne F, et al. ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues. Oncol Rep. 2016;36(3):1427–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Antoine M, Chenard MP, Piton N, Sabourin JC. Recommandations SFP- AFAQAP pour le testing ALK dans les CBNPC- mai 2017. Société Française de Pathologie 2017;
  7. 7.
    van der Wekken AJ, Pelgrim R, ‘t Hart N, et al. Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer. Clin Cancer Res. 2017;23:4251–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11:487–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Dagogo-Jack I, Shaw AT. Screening for ALK rearrangements in lung cancer: time for a new generation of diagnostics? Oncologist. 2016;21(6):662–3.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.CHRU Brest, Department of PathologyBrestFrance
  2. 2.Inserm, U1078BrestFrance
  3. 3.Department of PathologyUniversity Hospital MorvanBrestFrance

Personalised recommendations